|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-2-15
|
|
pubmed:abstractText |
Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:ChenKunK,
pubmed-author:ChesneyJasonJ,
pubmed-author:ChinKevinK,
pubmed-author:GrobJean-JacquesJJ,
pubmed-author:GuthrieTroyTJr,
pubmed-author:HoosAxelA,
pubmed-author:LebbéCelesteC,
pubmed-author:LinetteGeraldG,
pubmed-author:LutzkyJoseJ,
pubmed-author:NegrierSylvieS,
pubmed-author:NeynsBartB,
pubmed-author:O'DaySteven JSJ,
pubmed-author:SchadendorfDirkD,
pubmed-author:SmylieMichaelM,
pubmed-author:ThomasLucL,
pubmed-author:WaterfieldWilliamW,
pubmed-author:WolchokJedd DJD
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
155-64
|
|
pubmed:dateRevised |
2011-9-27
|
|
pubmed:meshHeading |
pubmed-meshheading:20004617-Adult,
pubmed-meshheading:20004617-Aged,
pubmed-meshheading:20004617-Aged, 80 and over,
pubmed-meshheading:20004617-Antibodies, Monoclonal,
pubmed-meshheading:20004617-Antineoplastic Agents,
pubmed-meshheading:20004617-Dose-Response Relationship, Drug,
pubmed-meshheading:20004617-Double-Blind Method,
pubmed-meshheading:20004617-Female,
pubmed-meshheading:20004617-Humans,
pubmed-meshheading:20004617-Male,
pubmed-meshheading:20004617-Melanoma,
pubmed-meshheading:20004617-Middle Aged,
pubmed-meshheading:20004617-Skin Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
|
|
pubmed:affiliation |
Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. wolchokj@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
